Review Article

Asian Jour Hosp Phar, Vol: 4, Issue: 4, 2024, 1-7

Asian Journal of Hospital Pharmacy

Content Available at www.ajhponline.com ISSN: 2583-0724

SINGLE-USE TECHNOLOGIES IN BIO MANUFACTURING: BENEFITS AND IMPLEMENTATION CHALLENGES

Sanket J Soni[1*], Ankitkumar N Patel [2]

[1*]Associate Director, Department of Project and Portfolio Management, Amneal Pharmaceuticals, New Jersey, USA.

[2] Director of Formulation, Department of Formulation R&D, Amneal Pharmaceuticals, New Jersey, USA.

Received: 04 Sept 2024 Revised: 19 Sept 2024 Accepted: 15 Oct 2024

Abstract

Single-use technologies (SUT) have revolutionized the bio manufacturing industry by offering flexibility, cost efficiency, and improved contamination control. Initially adopted for simpler processes, SUT has expanded to complex bioprocessing operations, driven by the growing demand for biologics, vaccines, and personalized medicines. This review explores the benefits of SUT, including reduced capital and operational expenditures, faster setup and turnaround times, and enhanced product safety. The scalability of SUT allows for rapid adaptation to market demands, significantly accelerating the time-to-market for critical therapies. However, the implementation of SUT is not without challenges. Material compatibility, leachables, waste management, and supply chain reliability pose significant hurdles. Moreover, regulatory and validation challenges complicate the adoption of these technologies in large-scale production. Case studies, including the rapid deployment of COVID-19 vaccines and the production of monoclonal antibodies, illustrate SUT's practical applications and benefits. The review also examines future trends, highlighting advances in materials, automation, and digital integration, as well as the expanding applications of SUT in cell and gene therapy manufacturing. As the bio manufacturing landscape continues to evolve, SUT will play a crucial role in meeting the industry's growing needs, provided the challenges associated with its implementation are effectively managed.

Keywords: Thyroid gland; Single-use technologies, bio manufacturing, contamination control, regulatory challenges, waste management, automation, digital integration.

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © 2024 Author(s) retains the copyright of this article.

***Corresponding Author**
Sanket J Soni

DOI: https://doi.org/10.38022/ajhp.v4i3.92

Introduction

Single-use technologies (SUT) refer to disposable components used in the bio manufacturing process, intended for one-time use before being discarded. These components include bioreactors, mixers, tubing, filters, and bags, all designed to replace traditional stainless-steel equipment [1]. The evolution of SUT began in the early 2000s when the biopharmaceutical industry recognized the need for more flexible, cost-effective, and rapid manufacturing solutions. Initially, single-use systems were adopted for simple processes like buffer preparation, but they have since expanded to more complex operations, including upstream and downstream bioprocessing. The development and refinement of these technologies have been driven by advancements in materials science, manufacturing processes, and regulatory acceptance, leading to their widespread adoption across the biopharmaceutical industry [2].

The adoption of SUT has significantly increased over the past two decades, mainly due to the growing demand for biologics, vaccines, and personalized medicines [3]. Biopharmaceutical companies, ranging from large multinational corporations to small biotech start-ups, have embraced SUT to address the challenges of traditional stainless-steel systems, such as high capital costs, long setup times, and complex cleaning and validation processes [4]. The flexibility and scalability of single-use systems are particularly advantageous in an industry where product lifecycles can be short, and demand for new therapies can surge unexpectedly. As a result, SUT has become a cornerstone of modern bio manufacturing, enabling companies to respond more quickly to market needs and regulatory requirements [5].

Importance of Single-Use Technologies in Modern Bio manufacturing

Single-use technologies play a crucial role in improving the flexibility of bio manufacturing processes. Unlike traditional stainless-steel systems, which require extensive cleaning and sterilization between batches, single-use components are pre-sterilized and can be rapidly deployed, reducing downtime and increasing operational efficiency. This flexibility is precious in multiproduct facilities, where quick changeovers are essential to meet diverse production demands [6]. Additionally, SUT reduces cleaning, validation, and maintenance costs, as there is no need for large-scale clean-in-place (CIP) and sterilize-in-place (SIP) systems. The disposable nature of SUT also minimises the risk of cross-contamination, enhancing product safety and compliance with regulatory standards. Furthermore, the scalability of single-use systems allows manufacturers to easily adjust production volumes, making them ideal for both small-scale clinical batches and large-scale commercial production. These benefits collectively enhance productivity, enabling bio manufacturers to bring products to market faster and more cost-effectively [7].

2. Scope and Objectives of the Review

This review aims to comprehensively analyse the benefits and challenges associated with implementing single-use technologies in bio manufacturing. While SUT offers numerous advantages regarding cost efficiency, flexibility, and contamination control, its adoption also presents challenges, including concerns about material compatibility, waste management, and supply chain reliability. This article thoroughly explores these benefits and challenges, drawing on case studies and industry examples to illustrate real-world applications and outcomes. By examining the current state of SUT in bio manufacturing, the review will highlight future trends and innovations likely to shape these technologies' continued evolution. The ultimate goal is to provide bio manufacturers with insights and strategies to effectively implement and optimise single-use systems in their production processes.

3. Benefits of Single-Use Technologies

Cost Efficiency

One of the most significant benefits of single-use technologies (SUT) is the reduction in both capital and operational expenditures. Traditional stainless-steel bio manufacturing facilities require substantial upfront investment in equipment, infrastructure, and utilities, such as clean-in-place (CIP) and sterilize-in-place (SIP) systems. In contrast, single-use systems eliminate the need for these expensive installations, as the disposable components come pre-sterilized and ready to use [8]. This reduces the capital expenditure required to establish a bio manufacturing facility. Additionally, operational costs are lowered as there is no need for extensive cleaning, sterilisation, or validation procedures between batches, which also minimises the need for water, chemicals, and energy consumption [9].

With single-use technologies, the costs associated with cleaning, sterilisation, and validation are significantly reduced. Traditional systems require rigorous cleaning protocols to prevent cross-contamination involving large amounts of water, detergents, and energy, as well as labour-intensive processes to ensure compliance with regulatory standards. Single-use systems, by contrast, eliminate the need for these processes, as the disposable components are discarded after use. This saves money and reduces the time needed to prepare the equipment for the next production run, thereby increasing overall efficiency [10].

Flexibility and Scalability

Single-use technologies offer unmatched flexibility in bio manufacturing, particularly in setup and turnaround times. Because these systems do not require extensive cleaning and sterilisation between batches, they can be set up and deployed much faster than traditional systems. This is particularly beneficial in facilities that produce multiple products or need to respond rapidly to changes in market demand. The ability to quickly switch between different production runs without lengthy downtime enhances operational agility and allows companies to meet customer needs more effectively [11].

Ease of Scaling Production Up or Down According to Demand, another critical advantage of single-use systems, is their scalability. Unlike traditional stainless-steel equipment, which is often designed for a specific production volume, single-use systems can be scaled up or down depending on production needs. This is particularly useful for biopharmaceutical companies that must produce varying batch sizes, such as during the transition from clinical trials to commercial production. The modular nature of single-use systems allows manufacturers to add or remove components as needed, providing the flexibility to adjust production capacity without significant additional investment [12].

Improved Contamination Control

Single-use technologies significantly reduce the risk of cross-contamination, a critical concern in bio manufacturing, mainly when producing multiple products in the same facility. Since the components are used only once and discarded, there is no risk of carryover contamination from previous batches [13]. This starkly contrasts traditional stainless-steel systems, where even the most rigorous cleaning and sterilization processes can leave behind residues that could contaminate subsequent batches. Using single-use components thus enhances product safety and ensures compliance with stringent regulatory standards [14].

In addition to reducing contamination risks, single-use systems improve overall product safety. The pre-sterilized nature of these components ensures that they meet high standards of cleanliness and purity, which is essential for maintaining the integrity of biopharmaceutical products. Regulatory bodies, such as the FDA and EMA, have increasingly recognized the benefits of single-use technologies, and their acceptance has paved the way for broader implementation across the industry. This has made it easier for manufacturers to achieve and maintain regulatory compliance, further enhancing the appeal of single-use systems [15].

Sustainability and Environmental Impact

Single-use technologies contribute to sustainability by reducing the water and energy required in the bio manufacturing process. Traditional systems consume vast amounts of water and energy for cleaning and sterilisation, which increases operational costs and has a significant environmental impact. On the other hand, single-use systems eliminate the need for these resource-intensive processes, resulting in a more sustainable production model. This reduction in resource consumption aligns with the growing emphasis on sustainability within the biopharmaceutical industry [16].

While single-use technologies generate waste as disposable plastics, they can still offer environmental benefits over traditional systems. The overall carbon footprint of single-use systems is often lower due to the reduced energy and water usage, and advancements in the development of biodegradable and recyclable single-use materials are helping to mitigate the impact of solid waste. Proper waste management practices, such as recycling and energy recovery, can further enhance the sustainability of single-use systems, making them an attractive option for environmentally conscious manufacturers [17].

Speed to Market

Single-use technologies can significantly accelerate the time-to-market for biopharmaceutical products. The reduced setup and validation times associated with these systems allow manufacturers to initiate production more quickly, which is particularly important in the competitive biopharmaceutical industry. This speed is a critical advantage when developing new biologics and vaccines, where rapid market entry can significantly impact patient outcomes and commercial success [18].

The advantage in Accelerating the Development of Biologics and Vaccines in the Context of Biologics and Vaccines, where timely availability can have life-saving implications, the speed offered by single-use systems is invaluable. The ability to quickly scale production in response to emerging health threats, such as during the COVID-19 pandemic, demonstrates the strategic importance of single-use technologies in rapidly developing and deploying critical therapies. This advantage makes single-use systems an essential tool for bio manufacturers looking to stay competitive and responsive to global health needs [19, 20].

Table 1: Technologies (SUT) in bio summarising the benefits of Single-Use manufacturing

Benefit	Description	Key Advantages
Cost Efficiency	- Reduction in capital and operational expenditures (CapEx and OpEx).	- Lower costs for equipment, cleaning, sterilization, and validation. - Reduced need for water, chemicals, and energy.
Flexibility and Scalability	- Rapid setup and quick turnaround times. - Easy scaling of production.	- Faster changeovers between batches. - Scalable to meet varying production demands, from small to large-scale.
Improved Contamination Control	- Single-use components reduce cross-contamination risks.	- Enhanced product safety. - Easier compliance with regulatory standards.
Sustainability and Environmental Impact	- Decreased water and energy usage. - Reduced carbon footprint and improved waste management.	- More sustainable operations. - Potential for biodegradable or recyclable single-use materials.
Speed to Market	- Faster production setup and validation processes.	- Accelerated development and time-to-market for biologics and vaccines. - Strategic advantage in responding to health emergencies (e.g., COVID-19 pandemic).

4. Implementation Challenges of Single-Use Technologies

Material Compatibility and Leachables

One of the primary challenges with single-use technologies (SUT) is ensuring material compatibility with biologics. The materials used in single-use components, such as plastics and elastomers, must not interact adversely with the biologic products. These interactions could alter the final product's efficacy or safety, making it essential to test and validate the materials used in single-use systems thoroughly [21].

Leachables and extractables can be released from single-use components into the biologic product during processing. These substances may come from the plastic materials, adhesives, or other components used to construct single-use systems. Leachables and extractables pose risks to product safety and patient health, requiring rigorous testing and monitoring to ensure these substances are within acceptable limits [22].

Waste Management and Environmental Concerns

While single-use technologies offer environmental benefits in terms of reduced water and energy use, they also generate significant amounts of plastic waste. Disposing of single-use plastics and bio-waste presents a challenge, as it requires effective waste management practices to prevent environmental harm. The increasing volume of waste generated by widespread adoption of SUT calls for innovative solutions, such as recycling programs or the development of biodegradable materials [23].

Single-use technologies must balance the environmental benefits of reduced resource consumption with the challenge of increased solid waste. While SUT minimises the need for energy-intensive cleaning and sterilisation processes, the trade-off is a higher volume of disposable materials that must be managed responsibly. This balance is crucial for the sustainable implementation of SUT in bio manufacturing [24].

Supply Chain Reliability

The reliance on single-use systems often means dependence on a limited number of suppliers who provide the critical components needed for production. This concentration of supply can create vulnerabilities in the supply chain, where disruptions at a key supplier could halt production. Ensuring a reliable and diversified supply chain is essential to mitigate the risks associated with this dependency [25].

Supply chain disruptions, whether due to geopolitical issues, natural disasters, or other unforeseen events, can severely impact the availability of single-use components. These disruptions can lead to production delays, shortages of critical products, and increased costs. Developing strategies to manage and mitigate these risks is critical for maintaining production continuity using single-use technologies [26].

Regulatory and Validation Challenges

Regulatory agencies, such as the FDA and EMA, have stringent requirements for the materials and processes used in bio manufacturing. Meeting these requirements can be challenging with single-use systems, as the materials are often new and may not have extensive regulatory history. Ensuring that single-use systems comply with all relevant regulations is complex and time-consuming [27].

Validating new materials and processes for single-use technologies can be difficult, as it involves demonstrating that they are safe, effective, and consistent. This validation process is critical for gaining regulatory approval but can be resource-intensive and may delay the implementation of single-use systems in production [28].

Cost Considerations for High-Volume Production

While single-use technologies offer cost savings in many scenarios, their cost-effectiveness in high-volume production must be carefully evaluated. For large-scale manufacturing, the recurring costs of disposable components may outweigh the savings from reduced cleaning and sterilization. This necessitates a thorough cost-benefit analysis to determine whether single-use systems are the most economical for high-volume production [29].

In high-volume production settings, traditional stainless-steel systems may still offer advantages in terms of durability and long-term cost savings. Comparing the costs and benefits of single-use versus traditional systems is essential to make informed decisions about which technology is best suited for a given production scale [30].

Table 2: implementation challenges of Single-Use Technologies (SUT) in bio manufacturing:

Challenge	Description	Key Issues
Material Compatibility and Leachables	Concerns about how materials in SUT interact with biologics.	- Potential interactions that could affect product safety. - Risks from leachables and extractables.
Waste Management and Environmental Concerns	Challenges in disposing of single-use plastics and managing biowaste.	- High volume of plastic waste. - Balancing environmental benefits with increased solid waste generation.
Supply Chain Reliability	Dependence on a few suppliers for critical components.	- Risk of production delays due to supply chain disruptions. - Need for a reliable and diversified supply chain.
Regulatory and Validation Challenges	Meeting regulatory standards and validating new materials and processes.	- Complex and time-consuming regulatory approval processes. - Challenges in validating new technologies.
Cost Considerations for High-Volume Production	Evaluating the cost-effectiveness of SUT in large-scale manufacturing.	- Higher recurring costs for disposable components. - Need to compare with traditional stainless-steel systems.

5. Case Studies and Industry Examples

Case Study: Implementation of SUT in Vaccine Manufacturing

The rapid development and deployment of COVID-19 vaccines highlighted the crucial role of single-use technologies (SUT) in accelerating bio manufacturing processes. During the pandemic, the flexibility and speed of SUT allowed vaccine manufacturers to scale up production to meet global demand quickly. Single-use systems enabled rapid facility setup, reduced the time required for equipment sterilization and validation, and facilitated faster changeovers between production runs. These advantages were instrumental in delivering millions of vaccine doses in record time, contributing significantly to the global pandemic response [31-33].

The successful deployment of SUT in COVID-19 vaccine production provided several key lessons and best practices.

One major lesson was the importance of supply chain agility and collaboration with suppliers to ensure the timely availability of single-use components. Additionally, the experience demonstrated the value of investing in scalable and flexible manufacturing systems that can be rapidly adapted to produce different products as needed. Best practices include maintaining strategic stockpiles of critical components and leveraging digital tools for real-time monitoring and process optimisation [34].

Case Study: Biologics Manufacturing

Single-use technologies have been widely adopted in the manufacturing of biologics, including monoclonal antibodies (mAbs). Companies like Amgen and Genentech have successfully implemented SUT to produce mAbs, benefiting from these systems' flexibility, cost savings, and reduced contamination risks. SUT has enabled these companies to quickly respond to changes in market demand, scale production efficiently, and maintain high product quality. The use of single-use bioreactors, mixers, and filtration systems has been particularly effective in streamlining the production process and reducing the need for large-scale stainless-steel infrastructure [35].

Despite the benefits, the implementation of SUT in biologics manufacturing has not been without challenges. Issues such as material compatibility, leachables, and the need for thorough validation have required careful consideration. Companies have addressed these challenges by conducting extensive pre-use testing of materials, working closely with suppliers to ensure the quality and consistency of single-use components, and implementing robust validation protocols. Additionally, investing in staff training and digital tools for monitoring and controlling the production process has been essential for overcoming these challenges and maximising the benefits of SUT [36, 37].

Comparison of Single-Use vs. Traditional Manufacturing in a Biotech Start-up

In a biotech start-up environment, the choice between single-use and traditional manufacturing systems can significantly impact cost, flexibility, and time-to-market. Start-ups often face resource constraints and the need for rapid product development, making SUT an attractive option. The lower capital expenditure (CapEx) required for single-use systems allows start-ups to allocate resources more efficiently. At the same time, the flexibility of SUT supports the production of multiple products or smaller batch sizes without the need for extensive reconfiguration [38].

Compared to traditional stainless-steel systems, SUT offers faster setup and validation times, which can be critical for start-ups looking to bring products to market quickly. However, the recurring costs of disposable components may be significantly higher in the long term, as production scales up. Start-ups must carefully evaluate the trade-offs between the upfront savings and the potential long-term costs. In many cases, the advantages of SUT in terms of flexibility and speed to market outweigh the challenges, making it a preferred choice for start-ups aiming to establish a foothold in the competitive biopharmaceutical industry [39, 40].

Table 3: Case Study - Implementation of SUT in Vaccine Manufacturing

Aspect	Details
Example	SUT in the production of COVID-19 vaccines.
Benefits	- Rapid facility setup and scaling. - Reduced time for sterilization and validation. - Faster changeovers between batches.
Lessons Learned	- Importance of supply chain agility. - Collaboration with suppliers for timely availability of components. - Value of scalable and flexible systems.
Best Practices	- Strategic stockpiles of critical components. - Use of digital tools for real-time monitoring and optimization.

Table 4: Comparison of Single-Use vs. Traditional manufacturing in a Biotech Start up

Aspect	Single-Use Technologies	Traditional Stainless-Steel Systems
Cost	Lower upfront capital expenditure (CapEx), higher recurring costs for disposables.	Higher CapEx, but potentially lower long-term costs.
Flexibility	High - Easily scalable, adaptable for multiple products and small batch sizes.	Lower - Requires extensive reconfiguration for different products.
Time-to-Market	Faster setup and validation, leading to quicker market entry.	Slower setup and validation, potentially delaying time-to-market.
Suitability for Startups	Ideal for startups needing quick, cost-effective entry into the market.	Better suited for established companies with stable, high-volume production needs.

Future Trends and Innovations in Single-Use Technologies

Significant advancements in materials and integration with digital technologies shape the future of single-use technologies (SUT) in bio manufacturing. One key trend is the development of new materials that offer improved compatibility with biologics and reduced leachables, addressing some of the primary concerns associated with SUT. Additionally, there is a growing focus on innovations in bioplastics and biodegradable materials, which aim to mitigate the environmental impact of single-use systems by providing more sustainable alternatives. These advancements enhance the safety and effectiveness of SUT and align with the industry's increasing emphasis on sustainability.

Another major trend is the integration of SUT with automation technologies and digital twins, transforming how bio-manufacturing processes are optimized and monitored in real-time. The combination of single-use systems with advanced automation enables more precise control over production parameters, leading to increased efficiency and reduced risk of human error. Hybrid manufacturing systems, which blend single-use and traditional stainless-steel technologies, are also emerging as a strategy to optimize production by leveraging the strengths of both approaches. Moreover, the expanding applications of SUT, particularly in cell and gene therapy manufacturing and personalized medicine, are opening new avenues for small-batch and flexible production, highlighting the versatility and growing importance of single-use technologies in the future of bio manufacturing.

Conclusion

Single-use technologies have become a cornerstone of modern biomanufacturing, offering significant advantages in terms of cost, flexibility, and speed to market. The ability to rapidly deploy and scale production systems without the extensive cleaning and validation required by traditional stainless-steel equipment has proven invaluable, particularly in the context of the COVID-19 pandemic. However, the widespread adoption of SUT also presents several challenges, including material compatibility, waste management, and regulatory hurdles. Addressing these challenges is critical for maximizing the benefits of SUT and ensuring its continued growth in the biopharmaceutical industry. Future innovations in material science, automation, and hybrid manufacturing systems will likely further enhance the capabilities of SUT, making it an even more integral part of biomanufacturing processes. As the industry continues to shift towards more personalized and flexible production models, the role of single-use technologies will only become more prominent, driving the next wave of innovation in biomanufacturing.

Funding

No

Acknowledgement

Nil

Conflict of Interest

No conflict of interest.

Informed Consent

Not applicable.

Ethical Statement

Not applicable.

Author Contribution

Sanket J Soni, Ankitkumar N Patel both are contributed equally.

References

1. Langer ES, Rogerson D. Single-use technologies: their impact on processing capabilities in biologics manufacturing. Pharm Bioprocess. 2015;3(1):9-18.
2. Liu HF, Ma J, Winter C, Bayer R. Current practices and challenges in using single-use technologies for viral vector manufacturing. BioProcess Int. 2020;18(3):18-27.
3. Cacciuttolo MA. Advances in single-use technology in the manufacture of biologics. Biotechnol J. 2018;13(7)
4. Shukla AA, Gottschalk U. Single-use disposable technologies for biopharmaceutical manufacturing. Trends Biotechnol. 2013;31(3):147-54.
5. Eibl R, Kaiser S, Löffelholz C, Eibl D. Disposable bioreactors: the current state-of-the-art and recommended applications in biotechnology. Appl MicrobiolBiotechnol. 2010;86(1):41-9.
6. Subramanian G. Single-use technology in biopharmaceutical manufacturing: a review of the current state of the industry. BioPharm Int. 2017;30(10):34-8.
7. Bisschops MM, Spierings LH. Single-use technologies in the upstream and downstream process of biopharmaceutical production. BioProcess Int. 2014;12(11):20-30.
8. Farid SS. Process economics of industrial monoclonal antibody manufacture. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;848(1):8-18.
9. Birch JR, Racher AJ. Antibody production. Adv Drug Deliv Rev. 2006;58(5-6):671-85.
10. Montaño LA, Middelberg APJ. Single-use bioreactors for microbial fermentation. Curr OpinChem Eng. 2018;22:7-13.
11. Sinclair A, Monge M, Xu P. The impact of single-use technologies on the economics of biopharmaceutical manufacturing. Bioprocess Int. 2010;8(6):26-31.
12. Klein D, Malmqvist E, Eriksson R, Lütkemeyer D. Implementation of single-use bioreactors for large-scale manufacture of therapeutic proteins. Pharm Bioprocess. 2016;4(1):25-34.
13. Phillips M, Katzer A. Regulatory challenges in the implementation of single-use technologies in biopharmaceutical manufacturing. Pharm Eng. 2015;35(6):1-5.
14. Eibl R, Eibl D. Application of single-use bioreactors in tissue engineering and cell-based therapies. Adv BiochemEngBiotechnol. 2011;123:139-57.
15. Eibl R, Eibl D. Design and use of the wave bioreactor for plant cell culture. In: Doran PM, editor. Plant Cell Culture Technology. Heidelberg: Springer-Verlag; 2013. p. 55-82.
16. Lim A, Kim JH, Kim S. Economic benefits of implementing single-use technologies in

manufacturing processes for biologics. J MicrobiolBiotechnol. 2017;27(7):1229-34.
17. Chon JH, Zarbis-Papastoitsis G. Advances in the production and downstream processing of antibodies. In: Jungbauer A, editor. Biotechnology of Plasma Proteins. Hoboken: John Wiley & Sons; 2012. p. 165-89.
18. Werth KD, Mun M, Yoon SH, Gerngross TU. Optimization and scale-up of a disposable bioreactor for microbial fermentation. BiotechnolBioeng. 2006;93(6):1210-21.
19. Zhang X, Ding W, Sun W. Development of a robust single-use bioreactor system for mammalian cell culture. Biotechnol Lett. 2014;36(9):1913-8.
20. Saracco L, Medolla F, Charrier A. Leveraging single-use systems for flexibility in multi-product facilities. BioPharm Int. 2019;32(6):18-23.
21. Zhang J, Zhou D, Lin Y. Recent advancements in single-use bioreactors: a comprehensive review. Biotechnol Adv. 2021;47:107697.
22. Mukhopadhyay T, Woodle M. Implementation of single-use technologies in the production of gene therapy vectors. Mol Ther Methods Clin Dev. 2019;13:135-44.
23. Ravella S, Angel M, Subramanian H, Thangavel N, Namballa M, Lokesh D, Mishra AK, Nagaraju GV. Navigating the Future of Cancer Diagnosis: A Comprehensive Review of Novel Approaches for Community-Based Treatment. future.;1:6.
24. Manda, P., Popescu, C., Juluri, A. et al. Micronized Zaleplon Delivery via Orodispersible Film and Orodispersible Tablets. AAPS PharmSciTech 19, 1358–1366 (2018).
25. Lakshmi Narasimha Rao, K., Praneeth Rao, K. Development and Validation of a Stability-Indicating LC Method for Determination of Bexarotene in Softgel Dosage Formulation. Chromatographia 80, 1211–1224 (2017).
26. Kakulamarri PR, Alikatte KL, Mateti UV (2016) Transdermal Iontophoresis of Non-Polar Drugs: A Mini Review. J Pharm Drug Deliv Res 5:3
27. Kakullamarri PR, Rao KLN (2017) Enhanced Bioavailability and Anticancer Activity of Vitamin Analogs. J BioequivAvailab 9: 439-441.
28. Rader RA. Single-use technology: advancements and adoption in bioprocessing. BioPharm Int. 2011;24(10):54-8.
29. Marichal-Gallardo P, Álvarez MM. State-of-the-art in downstream processing of monoclonal antibodies: process trends in design and validation. BiotechnolProg. 2020;36(2)
30. Cruz HJ, Freitas CM, Alves PM, Mota M. Bioprocess integration using single-use technologies: opportunities and challenges. BiotechnolProg. 2020;36(1)
31. Joseph B, Hussain A, Ahuja A. Digital transformation in biomanufacturing: leveraging automation and single-use technologies for flexible production. Pharm Eng. 2021;41(2):76-84.
32. Pollock J, Ho SV, Farid SS. Fed-batch and perfusion culture processes: economic, environmental, and operational feasibility under uncertainty. BiotechnolBioeng. 2013;110(8):2064-76.
33. Kumar KR, Nagaraju GV, Subrahmanyam SN, Nagarani K, Shareef S, Tennygilphin M, Namballa M. Assessment on Elements Involving the Academic Performance among Pharmacy Students: A Cross-Sectional Observational Study. Int J Cur Res Rev| Vol. 2021 Dec;13(23):141.
34. Küpper S, Reif O, Zimmermann A. Industrial production of therapeutic proteins: challenges in downstream processing. In: Horvath C, editor. Preparative Chromatography of Fine Chemicals and Pharmaceutical Agents. Amsterdam: Elsevier; 2019. p. 303-25.
35. Doran PM. Design of bioprocessing systems: considerations for single-use technology implementation. J Biotechnol. 2013;167(3):305-12.
36. Rathore AS, Agarwal H. Challenges and solutions in the development of single-use technologies for biomanufacturing. BioProcess Int. 2018;16(2):22-30.
37. Dherin C, Sommerfeld S, Lee J. Application of single-use technologies in the commercial manufacturing of therapeutic proteins. Pharm Bioprocess. 2017;5(3):131-8.
38. Forcina V, Mastroberardino L, Mori M. Integrating single-use technologies and continuous processing for the production of therapeutic proteins. Bioprocess Int. 2020;18(7):40-7.
39. Korhonen J, Rajamäki K. Cost-benefit analysis of single-use versus stainless-steel bioreactors: economic implications for commercial manufacturing. BioProcess Int. 2014;12(8):40-7.
40. McKnight TE, Zeng X, Bernasconi C. Single-use bioreactor applications in perfusion culture. BioProcess Int. 2017;15(10):58-64.